Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Expands By 168.4%

NeuroMetrix, Inc. (NASDAQ:NURO) saw a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 42,400 shares, an increase of 168.4% from the October 31st total of 15,800 shares. Based on an average trading volume of 18,200 shares, the days-to-cover ratio is currently 2.3 days. Approximately 2.9% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a report on Thursday. They set a “sell” rating on the stock.

NeuroMetrix Trading Up 0.3 %

Shares of NURO stock opened at $4.26 on Thursday. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The stock has a market capitalization of $8.69 million, a P/E ratio of -0.93 and a beta of 2.29. The firm’s 50 day moving average is $4.06 and its 200 day moving average is $3.83.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The company had revenue of $0.59 million during the quarter. During the same period in the prior year, the firm earned ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.